TY - JOUR
T1 - Changes in total parathyroid hormone (PTH), PTH-(1-84) and large C-PTH fragments in different stages of chronic kidney disease
AU - Herberth, J.
AU - Fahrleitner-Pammer, A.
AU - Obermayer-Pietsch, B.
AU - Krisper, P.
AU - Holzer, H.
AU - Malluche, H. H.
AU - Dobnig, H.
PY - 2006/5
Y1 - 2006/5
N2 - Introduction: Loss of renal function is accompanied by progressive increase in serum levels of intact parathyroid hormone (iPTH) in patients with end-stage renal disease (ESRD). There is a paucity of data regarding levels of PTH-(1-84) and its large carboxyl-terminal fragments (large C-PTH fragments) and progressive loss of kidney function in patients with chronic kidney disease (CKD). The current study was undertaken to describe the glomerular filtration rate (GFR)-dependent plasma concentrations of PTH-(1-84) and related large C-PTH fragments in adult patients with CKD by using different commercially available PTH assays. Methods: We studied 80 Caucasian patients with CKD stages 1 - 5 without renal replacement therapy. Creatinine clearance was calculated by the Modification of Diet in Renal Disease (MDRD) formula. Levels of iPTH were determined by second-generation assays (iPTH Elecsys® system, Roche Diagnostics; DUO total iPTH, Scantibodies Laboratory, Inc.; iPTH, Nichols Institute Diagnostics). Third-generation assays were used to measure PTH-(1-84) (CAP (cyclase activating PTH), Scantibodies; Bio-Intact PTH, Nichols). Levels of large C-PTH fragments and ratios of PTH-(1-84)/large C-PTH fragments were calculated and statistical analyses performed. Results: Levels of iPTH and PTH-(1-84) showed CKD s tage-dependent increases. Variations among the assays increased with progressive loss of kidney function. The assay from Scantibodies showed a GFR-dependent decrease of the ratio 1-84 PTH/large C-PTH fragment that was not observed with the Nichols assay. Conclusion: Increasing variations amon g the assays with progression of CKD emphasize the fact that the interpretation of measurements must take into consideration the specific assay. We found evidence for a possible preferential increase of the level of large C-PTH fragments over 1-84 PTH in a CKD stage-dependent manner (Scantibodies). The clinical implications of this finding have to be further evaluated by bone biopsy studies.
AB - Introduction: Loss of renal function is accompanied by progressive increase in serum levels of intact parathyroid hormone (iPTH) in patients with end-stage renal disease (ESRD). There is a paucity of data regarding levels of PTH-(1-84) and its large carboxyl-terminal fragments (large C-PTH fragments) and progressive loss of kidney function in patients with chronic kidney disease (CKD). The current study was undertaken to describe the glomerular filtration rate (GFR)-dependent plasma concentrations of PTH-(1-84) and related large C-PTH fragments in adult patients with CKD by using different commercially available PTH assays. Methods: We studied 80 Caucasian patients with CKD stages 1 - 5 without renal replacement therapy. Creatinine clearance was calculated by the Modification of Diet in Renal Disease (MDRD) formula. Levels of iPTH were determined by second-generation assays (iPTH Elecsys® system, Roche Diagnostics; DUO total iPTH, Scantibodies Laboratory, Inc.; iPTH, Nichols Institute Diagnostics). Third-generation assays were used to measure PTH-(1-84) (CAP (cyclase activating PTH), Scantibodies; Bio-Intact PTH, Nichols). Levels of large C-PTH fragments and ratios of PTH-(1-84)/large C-PTH fragments were calculated and statistical analyses performed. Results: Levels of iPTH and PTH-(1-84) showed CKD s tage-dependent increases. Variations among the assays increased with progressive loss of kidney function. The assay from Scantibodies showed a GFR-dependent decrease of the ratio 1-84 PTH/large C-PTH fragment that was not observed with the Nichols assay. Conclusion: Increasing variations amon g the assays with progression of CKD emphasize the fact that the interpretation of measurements must take into consideration the specific assay. We found evidence for a possible preferential increase of the level of large C-PTH fragments over 1-84 PTH in a CKD stage-dependent manner (Scantibodies). The clinical implications of this finding have to be further evaluated by bone biopsy studies.
KW - Bio-intact PTH
KW - Chronic kidney disease
KW - PTH assays
KW - PTH-(1-84), large C-PTH fragments
KW - Parathyroid hormone
KW - Total PTH, intact PTH
UR - http://www.scopus.com/inward/record.url?scp=33646388960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646388960&partnerID=8YFLogxK
U2 - 10.5414/CNP65328
DO - 10.5414/CNP65328
M3 - Article
C2 - 16724653
AN - SCOPUS:33646388960
SN - 0301-0430
VL - 65
SP - 328
EP - 334
JO - Clinical Nephrology
JF - Clinical Nephrology
IS - 5
ER -